Treating Heparin-Induced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation
Retrospective case series published in The Israel Medical Association journal : IMAJ (2023)
Abstract
BACKGROUND: Unfractionated heparin is the preferred anticoagulant used during open heart surgeries, including left ventricular assist device (LVAD) implantation. In cases in which patients are heparin-induced thrombocytopenia positive (HIT+), the accepted practice has been to substitute heparin with bivalirudin. This practice may be associated with significant bleeding and adverse outcomes. OBJECTIVES: To review our experience with HIT+ patients who were heparin-induced thrombocytopenia with thrombosis negative (HITT-) and who underwent HeartMate 3 LVAD implantation using heparin intraoperatively rather than bivalirudin. METHODS: From 2016 to 2022, 144 adult patients were implanted with HeartMate 3 LVAD at our center. Among them, 7 were detected as HIT+ but HITT- and therefore were prescribed intraoperatively with heparin and treated pre- and postoperatively with bivalirudin. We reviewed the preoperative, intraoperative, and postoperative characteristics as well as short-term mortality and the complication rates of these HIT+ patients. RESULTS: The median age of our cohort was 56 years (51-60), 71% were male (n=5), all were INTERMACS Level 1, and most were bridged to transplant (n=6, 86%). The 30-day mortality rate post-implantation was 0%. The average 24-hour chest drain postoperative output was 1502.86 ± 931.34 ml. There were no intraoperative pump thromboses, perioperative thromboses, cerebrovascular accidents, or gastrointestinal bleeding within the first 24 hours postoperative. One patient required a revision due to bleeding. CONCLUSIONS: Intraoperative unfractionated heparin may be administered to patients who are HIT+ and HITT- while undergoing LVAD implantation. However, further investigation is required.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
A retrospective review of 7 HIT+/HITT- patients undergoing HeartMate 3 LVAD implantation with intraoperative heparin plus pre- and postoperative bivalirudin, reporting 0% 30-day mortality and no intraoperative pump thromboses.
Why This Matters for Hirudotherapy
This single-center case series reviewed 7 patients who were heparin-induced thrombocytopenia positive but thrombosis negative (HITT-) and underwent HeartMate 3 LVAD implantation using intraoperative unfractionated heparin with pre- and postoperative bivalirudin, reporting 0% 30-day mortality, no perioperative thromboses, and one bleeding-related revision. Bivalirudin is a direct thrombin inhibitor modeled on hirudin from the medicinal leech secretome, and clinical data on its perioperative use in high-risk cardiac surgery directly inform understanding of how hirudin-class anticoagulants perform in practice. The findings suggest a potential strategy for limiting intraoperative bivalirudin exposure in this setting; however, the very small sample (n=7), observational design, single-center experience, and short follow-up render the results hypothesis-generating only, not proof of efficacy or safety.
Citation
Reference (Vancouver style)
Eisenberger J, Somer S, Ram E, Nachum E, Frogal J, Levin S, et al. Treating Heparin-Induced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation. Isr Med Assoc J. 2023;25(11):757-759. PMID: 37980622
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026